These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24837225)

  • 1. MicroRNAs: potential therapeutic targets in diabetic complications of the cardiovascular and renal systems.
    Figueira MF; Monnerat-Cahli G; Medei E; Carvalho AB; Morales MM; Lamas ME; da Fonseca RN; Souza-Menezes J
    Acta Physiol (Oxf); 2014 Jul; 211(3):491-500. PubMed ID: 24837225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNAs: the underlying mediators of pathogenetic processes in vascular complications of diabetes.
    Ruiz MA; Chakrabarti S
    Can J Diabetes; 2013 Oct; 37(5):339-44. PubMed ID: 24500562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics.
    Jakubik D; Fitas A; Eyileten C; Jarosz-Popek J; Nowak A; Czajka P; Wicik Z; Sourij H; Siller-Matula JM; De Rosa S; Postula M
    Cardiovasc Diabetol; 2021 Feb; 20(1):55. PubMed ID: 33639953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentially expressed microRNAs and their target genes in the hearts of streptozotocin-induced diabetic mice.
    Diao X; Shen E; Wang X; Hu B
    Mol Med Rep; 2011; 4(4):633-40. PubMed ID: 21584493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanism of diabetic cardiomyopathy and modulation of microRNA function by synthetic oligonucleotides.
    Ghosh N; Katare R
    Cardiovasc Diabetol; 2018 Mar; 17(1):43. PubMed ID: 29566757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting miRNA for Therapy of Juvenile and Adult Diabetic Cardiomyopathy.
    Nandi SS; Mishra PK
    Adv Exp Med Biol; 2018; 1056():47-59. PubMed ID: 29754174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-transcriptional gene-expression regulation by micro RNA (miRNA) network in renal disease.
    Kaucsár T; Rácz Z; Hamar P
    Adv Drug Deliv Rev; 2010 Nov; 62(14):1390-401. PubMed ID: 20940025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status and strategies of long noncoding RNA research for diabetic cardiomyopathy.
    Pant T; Dhanasekaran A; Fang J; Bai X; Bosnjak ZJ; Liang M; Ge ZD
    BMC Cardiovasc Disord; 2018 Oct; 18(1):197. PubMed ID: 30342478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review: The role of microRNAs in kidney disease.
    Li JY; Yong TY; Michael MZ; Gleadle JM
    Nephrology (Carlton); 2010 Sep; 15(6):599-608. PubMed ID: 20883280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between downregulation of miRNAs and increase of oxidative stress in the development of diabetic cardiac dysfunction: junctin as a target protein of miR-1.
    Yildirim SS; Akman D; Catalucci D; Turan B
    Cell Biochem Biophys; 2013; 67(3):1397-408. PubMed ID: 23723006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Where are we in diabetic nephropathy: microRNAs and biomarkers?
    McClelland A; Hagiwara S; Kantharidis P
    Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):80-6. PubMed ID: 24247820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid metabolism and its implications for type 1 diabetes-associated cardiomyopathy.
    Ritchie RH; Zerenturk EJ; Prakoso D; Calkin AC
    J Mol Endocrinol; 2017 May; 58(4):R225-R240. PubMed ID: 28373293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exercise as A Potential Therapeutic Target for Diabetic Cardiomyopathy: Insight into the Underlying Mechanisms.
    Seo DY; Ko JR; Jang JE; Kim TN; Youm JB; Kwak HB; Bae JH; Kim AH; Ko KS; Rhee BD; Han J
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31842522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNAs: Potential Targets in Diabetic Retinopathy.
    Li X; Yu ZW; Wang Y; Fu YH; Gao XY
    Horm Metab Res; 2020 Mar; 52(3):142-148. PubMed ID: 32215885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging Roles for MicroRNAs in Diabetic Microvascular Disease: Novel Targets for Therapy.
    Zhang Y; Sun X; Icli B; Feinberg MW
    Endocr Rev; 2017 Apr; 38(2):145-168. PubMed ID: 28323921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of LncRNA MIAT in Diabetic Complications.
    Wang L; Wang H; Luo Y; Wu W; Gui Y; Zhao J; Xiong R; Li X; Yuan D; Yuan C
    Curr Med Chem; 2024; 31(13):1716-1725. PubMed ID: 37711129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of microRNAs in the modulation of diabetic retinopathy.
    Mastropasqua R; Toto L; Cipollone F; Santovito D; Carpineto P; Mastropasqua L
    Prog Retin Eye Res; 2014 Nov; 43():92-107. PubMed ID: 25128741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of non-coding RNAs in diabetic nephropathy: potential applications as biomarkers for disease development and progression.
    Alvarez ML; Distefano JK
    Diabetes Res Clin Pract; 2013 Jan; 99(1):1-11. PubMed ID: 23102915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of microRNAs in the pathophysiology, diagnosis, and treatment of diabetic cardiomyopathy.
    Abdel Rhman M; Owira P
    J Pharm Pharmacol; 2022 Nov; 74(12):1663-1676. PubMed ID: 36130185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered retinal microRNA expression profiles in early diabetic retinopathy: an in silico analysis.
    Xiong F; Du X; Hu J; Li T; Du S; Wu Q
    Curr Eye Res; 2014 Jul; 39(7):720-9. PubMed ID: 24502381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.